Efficacy analysis of Roxadustat capsules and recombinant human erythropoietin injection in treating anemia in hemodialysis patients with renal disease
罗沙司他胶囊与重组人促红素注射液治疗血液透析肾性贫血的疗效分析

摘要

目的 探讨罗沙司他胶囊与重组人促红素注射液治疗血液透析肾性贫血的疗效。方法 收集2024年6月-2024年12月期间进行长期血液透析治疗的40例患者资料，作为对照组（n=40例，重组人促红素注射液治疗）。再收集2025年1月-2025年6月期间的40例同类患者资料，作为观察组（n=40例，联合罗沙司他胶囊与重组人促红素注射液治疗）。对比两组临床疗效。结果 观察组的各项铁代谢指标、贫血指标、临床治疗效果，均显著优于对照组，且炎症因子水平明显更低，差异均有统计学意义（P＜0.05）；两组不良反应发生率并无明显差异（P＞0.05）。结论 联合使用罗沙司他胶囊与重组人促红素注射液治疗血液透析肾性贫血，可有效改善铁代谢、贫血相关指标，减轻机体炎症反应，具有较高安全性，疗效更佳。

Abstract

Objective Exploring the efficacy of Roxadustat capsules and recombinant human erythropoietin injection in treating anemia of hemodialysis patients.
Methods Data from 40 patients undergoing long-term hemodialysis between June 2024 and December 2024 were collected as the control group (n=40, treated with recombinant human erythropoietin injection). Another 40 patients with similar conditions from January 2025 to June 2025 were collected as the observation group (n=40, treated with a combination of Roxadustat capsules and recombinant human erythropoietin injection). The clinical efficacy of both groups was compared.
Results The observation group showed significantly better iron metabolism indicators, anemia-related indicators, and clinical treatment outcomes compared to the control group, with markedly lower inflammatory factor levels, all differences being statistically significant (P<0.05). There was no significant difference in adverse reaction rates between the two groups (P>0.05).
Conclusion   The combined use of Roxadustat capsules and recombinant human erythropoietin injection effectively improves iron metabolism and anemia-related indicators, reduces systemic inflammatory responses, and demonstrates higher safety with superior efficacy in treating anemia of hemodialysis patients.